Real-world Evidence for SEmaglutide Treatment in Murakami memorial hospital - RESET study

Murakami Memorial Hospital0 个研究点目标入组 49 人开始时间: 2020年7月6日最近更新: 2023年10月17日

研究概览

简要总结

Total HbA1c0week7.24,16week6.80(%) GA0week15.9,16week14.3(%) Body weight0week82.46,16week76.77(kg) Add on OHA group(A)HbA1c 0week7.18,16week6.74(%),Change from another GLP-1RA(G)HbAc0week7.29,16week6.585(%),G Body weight 0week81.69,16week79.14(kg) HbA1c significant reduction and Body weight loss using SEmaglutide.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 90years-old（—）
性别: All

入选标准

未提供

排除标准

•Severe renal impairment (eGFR<30ml/min/1.73m2, end stage at CKD and dialysis) (dialysis and eGFR less than 30 ml/min)

研究者

发起方

Murakami Memorial Hospital

相似试验

已完成

不适用

Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 DiabetesDiabetes Mellitus, Type 2

NCT06507475Novo Nordisk A/S209

已完成

3 期

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)ObesityDiabetes Mellitus, Type 2

NCT05514535Novo Nordisk A/S573

已完成

3 期

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or ObesityOverweightObesity

NCT03811574Novo Nordisk A/S401

已完成

3 期

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2

NCT03191396Novo Nordisk A/S577

进行中（未招募）

1 期

Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetesDiabetes Mellitus, Type 2MedDRA version: 17.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861

EUCTR2013-004392-12-ROovo Nordisk A/S1,082